Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypoglycemia Incidence in Insulin Glargine Dosing Switch
NCT00609895Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine in diabetes mellitus (DM), sponsored by Sanofi. Primary endpoint: Percentage of subjects with glucose <= 56 mg/dL. Started Jan 2004; status: completed.
02
Drugs
insulin glargine
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT00609895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00609895.